These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 17521177

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. 3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach.
    Chen JZ, Han XW, Liu Q, Makriyannis A, Wang J, Xie XQ.
    J Med Chem; 2006 Jan 26; 49(2):625-36. PubMed ID: 16420048
    [Abstract] [Full Text] [Related]

  • 3. Development of CoMFA and CoMSIA models of affinity and selectivity for indole ligands of cannabinoid CB1 and CB2 receptors.
    De Freitas GB, da Silva LL, Romeiro NC, Fraga CA.
    Eur J Med Chem; 2009 Jun 26; 44(6):2482-96. PubMed ID: 19249138
    [Abstract] [Full Text] [Related]

  • 4. Combined 3D QSAR and molecular docking studies to reveal novel cannabinoid ligands with optimum binding activity.
    Durdagi S, Papadopoulos MG, Papahatjis DP, Mavromoustakos T.
    Bioorg Med Chem Lett; 2007 Dec 15; 17(24):6754-63. PubMed ID: 17980589
    [Abstract] [Full Text] [Related]

  • 5. C1'-cycloalkyl side chain pharmacophore in tetrahydrocannabinols.
    Papahatjis DP, Nahmias VR, Nikas SP, Andreou T, Alapafuja SO, Tsotinis A, Guo J, Fan P, Makriyannis A.
    J Med Chem; 2007 Aug 23; 50(17):4048-60. PubMed ID: 17672444
    [Abstract] [Full Text] [Related]

  • 6. Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1'.
    Papahatjis DP, Nikas SP, Kourouli T, Chari R, Xu W, Pertwee RG, Makriyannis A.
    J Med Chem; 2003 Jul 17; 46(15):3221-9. PubMed ID: 12852753
    [Abstract] [Full Text] [Related]

  • 7. Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study.
    Montero C, Campillo NE, Goya P, Páez JA.
    Eur J Med Chem; 2005 Jan 17; 40(1):75-83. PubMed ID: 15642412
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Unsaturated side chain beta-11-hydroxyhexahydrocannabinol analogs.
    Busch-Petersen J, Hill WA, Fan P, Khanolkar A, Xie XQ, Tius MA, Makriyannis A.
    J Med Chem; 1996 Sep 13; 39(19):3790-6. PubMed ID: 8809166
    [Abstract] [Full Text] [Related]

  • 10. Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
    Brogi S, Corelli F, Di Marzo V, Ligresti A, Mugnaini C, Pasquini S, Tafi A.
    Eur J Med Chem; 2011 Feb 13; 46(2):547-55. PubMed ID: 21183257
    [Abstract] [Full Text] [Related]

  • 11. Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling.
    Stern E, Muccioli GG, Millet R, Goossens JF, Farce A, Chavatte P, Poupaert JH, Lambert DM, Depreux P, Hénichart JP.
    J Med Chem; 2006 Jan 12; 49(1):70-9. PubMed ID: 16392793
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Combined CoMFA and CoMSIA 3D-QSAR study of benzimidazole and benzothiophene derivatives with selective affinity for the CB2 cannabinoid receptor.
    Romero-Parra J, Chung H, Tapia RA, Faúndez M, Morales-Verdejo C, Lorca M, Lagos CF, Di Marzo V, David Pessoa-Mahana C, Mella J.
    Eur J Pharm Sci; 2017 Apr 01; 101():1-10. PubMed ID: 28137469
    [Abstract] [Full Text] [Related]

  • 14. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
    Bhongade BA, Gadad AK.
    J Med Chem; 2006 Jan 26; 49(2):475-89. PubMed ID: 16420035
    [Abstract] [Full Text] [Related]

  • 15. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
    Zhu YQ, Lei M, Lu AJ, Zhao X, Yin XJ, Gao QZ.
    Eur J Med Chem; 2009 Apr 26; 44(4):1486-99. PubMed ID: 18771818
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs.
    Krishnamurthy M, Gurley S, Moore BM.
    Bioorg Med Chem; 2008 Jul 01; 16(13):6489-500. PubMed ID: 18524604
    [Abstract] [Full Text] [Related]

  • 18. Development of a novel class of monocyclic and bicyclic alkyl amides that exhibit CB1 and CB2 cannabinoid receptor affinity and receptor activation.
    Berglund BA, Fleming PR, Rice KC, Shim JY, Welsh WJ, Howlett AC.
    Drug Des Discov; 2000 Jul 01; 16(4):281-94. PubMed ID: 10807034
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.